161 men and postmenopausal women undergoing treatment with internal fixation for a unilateral femoral neck fracture resulting from a low-trauma event were randomized in two concurrent trials to receive either Teriparatide or a placebo once daily for 6 months. This study was conducted to determine if the benefits observed in revision rates, radiographic healing, and clinical outcomes with the use of Teriparatide in preclinical and preliminary clinical data were replicable in a hip fracture patients. Due to the slow accrual of patients enrollment was stopped early in these trials well before the planed sample size was reached. The analysis of the patients who were enrolled indicated that the use of Teriparatide did not provide a reduction in the risk of revision surgery, improve signs of radiographic healing, or decrease pain when compared to a placebo. These results should be interpreted with caution as the small sample size limited the power of this study to detect potential differences. Larger well designed randomized controlled trials are needed to further investigate the effects of Teriparatide in bone healing.